Compounding in Dermatology Update – Part 2
916691669166
In part 1 of this 2-part series, Dr. Kircik along with JDD authors Vlatka Agnetta MD, Abel Torres MD JD MBA, Seemal R. Desai MD, and Adelaide A. Hebert MD, reviewed the regulatory landscape of compounding in dermatology, including federal and state regulations. In part 2, they discuss FDA and USP Compounding Lists/ Categories and provide their final thoughts on in-office compounding.
FDA Compound …
In part 1 of this 2-part series, Dr. Kircik along with JDD authors Vlatka Agnetta MD, Abel Torres MD JD MBA, Seemal R. Desai MD, and Adelaide A. Hebert MD, reviewed the regulatory landscape of compounding in dermatology, including federal and state regulations. In part 2, they discuss FDA and USP Compounding Lists/ Categories and provide their final thoughts on in-office compounding.
FDA Compound … Continue reading "Compounding in Dermatology Update – Part 2"
JDD Author and Senior Associate Editor, Dr. Leon Kircik, dives into the controversial and confusing landscape of in-office medication compounding.
In-office compounding, once part and parcel of dermatologic practice, has become increasingly controversial—and confusing. As a result of legitimate public health concerns, FDA scrutiny began with compounding facilities. Unfortunately, regulatory f … 